



## **Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference**

March 6, 2024

TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- [Pacira BioSciences, Inc.](https://www.pacira.com) (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26<sup>th</sup> Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the "Events" page of the company's website at [investor.pacira.com](https://investor.pacira.com). A replay of the webcast will also be available for two weeks following the event.

### **About Pacira**

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit [www.pacira.com](https://www.pacira.com).

Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 [Christian.pedetti@pacira.com](mailto:Christian.pedetti@pacira.com)